Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-27
2007-02-27
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
09868196
ABSTRACT:
This invention relates to the field of cancer therapy. More particularly, the invention relates to the treatment of mammary tumor, clinically manifest mammary tumor (breast cancer) and metastatic mammary tumor by administration of human Chorionic Gonadotropin (hCG). The treatment preferably comprises the administration of hCG in conjunction with an antiestrogen and/or a Type I Interferon.
REFERENCES:
patent: 5677275 (1997-10-01), Lunardi-Iskandar et al.
patent: 5700781 (1997-12-01), Harris
patent: 5877148 (1999-03-01), Lunardi-Iskandar et al.
patent: WO 85/01959 (1985-05-01), None
patent: WO 96/04008 (1996-02-01), None
patent: WO 97/494432 (1997-12-01), None
Grattarola (1976, Journal of the National Cancer Institute, vol. 56, pp. 11-16).
Saal et al, Fertil Steril. Aug. 1991;56(2):225-9.
Anapliotou et al, Fertil Steril. Aug. 1996;66(2):305-11.
Silverstein et al (1994, Cancer, vol. 73, pp. 1673-1677, abstract only).
Platanias et al (J Biol Chem. Mar. 6, 1998;273:5577-81).
Oberg et al (1989, J Natl Cancer Inst., vol. 81, pp. 531-535).
Recchia et al (Clin Ter. May-Jun. 1998;149:203-8).
Sigma catalog (1995, p. 263 only).
Robinson et al (1990, Breast Cancer Res. Treat., vol. 15, pp. 95-101, Sep. 4, 2003.
Albini, et al., “The β-core fragment of human chorionic gonadotrophin inhibits growth of kaposi's sarcoma-derived cells and a new immortalized kaposi's sarcoma cell line”,Aids, 1997, 11, 713-721.
Allegra, J.C. “Reviews on endocrine related cancer”, Paterson AHG, Lees Aw eds Suppl, 1984, 14, 115-119.
Alvardo, et al., “Human chorionic gonadotropin inhibits proliferation and induces expression of inhibin in human breast epithelial cells in vitro”,In Vitro 30A, 1994, 4-8.
Bernstein, et al., “Treatment with human chorionic gonadotropin and risk of breast cancer”,Cancer Epidemiol., Biomarkers and Prev. 1995, 4, 437-440.
Dias, J.A. et al., “Receptor binding and functional properties of chimeric human follitropin prepared by an exchange between a small hydrophilic intercysteine loop of human follitropin and human lutropin”,J. Biol. Chem., 1994, 269(41), 25289-25294.
Pouillart, P. et al., “Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone recepotrs”,Eur. J. Cancer Clin. Oncol., 1982, 18, 929-935.
Gill, et al., “Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous kaposi's sarcoma”,J. Natl Cancer Inst., 1997, 89, 1797-1802.
Grossman, M.et al., “Substitution of the seat-belt region of the thyroid-stimulating hormone(TSH) β-subunit with the corresponding regions of choriogonadotropin or follitropin confers luteotropic but not follitropic activity ti chimeric TSH”,J. Biol. Chem, 1997, 272(24), 15532-15540.
Baulieu E.E. et al, Glycoprotein hormones: gonadotropins and thyrotropin. In Hormones-From molecules to Disease.Chapman and Hall, N.Y. and London, 1990, 257-275.
Legha, et al., “Antiestrogens in the treatment of breast cancer”,Cancer Treat. Rev.1976, 3, 205.
Lunardi-Iskandar, et al., “Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease”Nature Med, 1998, 4, 428-434.
Mgbonyebi, et al., “Induction of reversible growth arrest of immortal and neoplastic human breast epithelial cells by human chorionic gonadotropin”,Proc. Annu. Meet. A, Soc. Cancer Res.,1997, pp A1977, XP002109660.
Natoli, C. et al., “Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line”,Breast Cancer Res Treat, 1983, 3, 23-32.
Russo, et al., “Physiological bases of breast cancer prevention”Euro J. Cancer Prevention, 1993, 2, 101-111.
Russo, et al., “Is differentation the answer in breast cancer prevention?”Inter. Res. Com, 1982,10, 935-945.
Russo, et al., “Susceptibility of the mammary gland to carcinogenesis”,Am J. Pathol, 1979, 96, 721-734.
Russo, et al., “Developmental stage of the rat mammary gland as determinant of its susceptibility to 7, 12-Dimethylbenz[a]anthracene”,J. Natl. Cancer Inst.1978, 61, 1439-1442.
Russo, et al., Biology of Disease, “Biological and Molecular bases of Mammary Carcinogenesis”,Lab Invest, 1987, 57, 112-137.
Russo, et al., “Human chorionic gonadotropin and rat mammary cancer prevention”J. Natl. Cancer Inst., 1990, 82, 1286-1289.
Russo, et al., “Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis”,Br. J. Cancer, 1990, 62, 2343-2347.
Russo, et al., “Influence of differentation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis”,Cancer Res., 1980, 40, 2677-2687.
Russo, et al., “Susceptibility of the mammary gland to carcinogenesis”Am. J. Pathol, 1980, 100, 497-511.
Samaneigo, F. et al., “Induction of programmed cell death in kaposi's sarcoma cells preparations of human chorionic gonadotropin”J. Natl. Cancer Inst., 1999, 91, 135-143.
Srivastava, et al., “Chorionic gonadotropin inhibits rat mammary carcinogenesis through activation of programmed cell death”,Carcinogenesis, 1997, 18, 1799-1808.
Srivastava, P. et al., “Growth inhibition and activation of apoptotic gene expression by human chorionic gonadotropin in human breast epithelial cells”,Anticancer Research, 1998, 18, 4003-4010.
Srivastava, P. et al., “Identification of new genes differentially expressed in breast carcinoma cells treated with human chorionic gonadotropin”,Int'l Jrl of Oncology, 1998, 13, 465-469.
You, et al., “direct modulation of tumor suppressor connexin 26 gene by human chorionic gonadotropin in rat mammary glands”,Cancer Research, 1998, 58/7, 1498-1502.
Deluca Giampiero
Janssens Jaak
Russo Irma H.
Russo Jose
Applied Research Systems ARS Holdings N.V.
Drinker Biddle & Reath LLP
Fox Chase Cancer Center
Reed Janet E.
Yu Misook
LandOfFree
hCG therapy for the treatment of breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with hCG therapy for the treatment of breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and hCG therapy for the treatment of breast cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3885396